Rilexine 300 mg Tablets for Dogs

מדינה: הממלכה המאוחדת

שפה: אנגלית

מקור: VMD (Veterinary Medicines Directorate)

מרכיב פעיל:

Cefalexin

זמין מ:

Virbac

קוד ATC:

QJ01DB01

INN (שם בינלאומי):

Cefalexin

טופס פרצבטיות:

Tablet

סוג מרשם:

POM-V - Prescription Only Medicine – Veterinarian

קבוצה תרפויטית:

Dogs

איזור תרפויטי:

Antimicrobial

מצב אישור:

Authorized

תאריך אישור:

2005-10-24

מאפייני מוצר

Revised: May 2022
AN: 01398/2021
Page 1 of 5
SUMMARY OF THE PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Rilexine 300 mg Tablets for dogs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains:
- Active substance
Cefalexin
………………………………………………….300 mg
(as Cefalexin Monohydrate)
For the full list of excipients see section 6.1.
3. PHARMACEUTICAL FORM
Tablets.
Creamy oblong tablet with small brown spots marked with a score-line.
The tablets can be divided into halves.
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bacterial skin infections in dogs (including deep
and superficial
pyodermas) caused by organisms susceptible to Cefalexin.
For the treatment of urinary-tract infections in dogs (including
nephritis and cystitis) caused
by organisms susceptible to Cefalexin.
4.3 CONTRA-INDICATIONS
Do not use in animals known to be hypersensitive to penicillins and
cephalosporins.
Do not use in rabbits, guinea pigs, hamsters and gerbils.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As with other antibiotics which are excreted mainly by the kidneys,
unnecessary
accumulation may occur in the body when renal function is impaired. In
case of known
renal insufficiency, the dose should be reduced and antimicrobials
known to be
nephrotoxic should not be administered concurrently.
Revised: May 2022
AN: 01398/2021
Page 2 of 5
This product should not be used to treat puppies of less than 1 kg of
bodyweight.
Use of the product deviating from the instructions given in the SPC
may increase the
prevalence of bacteria resistant to Cefalexin and may decrease the
effectiveness of
treatment with penicillins due to the potential for cross-resistance.
Use of the product should be based on susceptibility testing of the
bacteria isolated from
the animal. If this is not possible, therapy should be based on local
epidemiological